---

Highlights of May 2022

1. Biocon Biologics may close $3.34 billion Viatris deal by end of June 2022.

2.    Eris Lifesciences acquires Oaknet Healthcare for INR 650 crores (~USD 90M).

3.    Excelra, HotSpot Therapeutics partner for treatment of cancer, autoimmune disease.

4.    Avantor, Cytovance Biologics collaborate for plasmid DNA development.

5.    Orion enters into exclusive agreement with Jemincare.

6.    DNA Script partners with Premas Life Sciences for 'Same-day Enzymatic DNA Synthesis'.

7.    SciSparc unlocks nasal cannabinoid delivery via Polyrizon pact.

8.    Stevanato inks auto-injector deal to continue drug delivery push.

9.    Immedica enters agreement with OrphanPacific.

10.    China’s Pharmaron acquires commercial API manufacturing facility in USA.

11.    An exclusive licensing agreement has been agreed by SunRock Biopharma, and Ellipses Pharma.

Highlights at Aagami:

1.      Aagami received another year long assignment from Past Client

2.      Aagami received a contract extension from another client

3.      Aagami is overbooked (45+ meetings) for BIO International Convention 2022 (June 13-16, San Diego), with 16 more meetings accepted and yet to be scheduled. If you would like to meet, please consider meeting us digitally in the week of June 20 or later. 

INFOCUS: Select opportunities available:

For Acquisition:

1.      Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns. Available at a very reasonable price.

For Partnering/Licensing/ Investment:

1.   Investment in the US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications.
2. Licensing, Co-development - 505(b)(2) low cost near market IP protected Bendamustine. Can be brought to market in 2024 without any infringement. Negligible competition (3) at the moment. Good market share potential.
3.  Licensing/Strategic Partnership: Next-gen AI powered imaging to pinpoint the IVF +/- 12 hour window of opportunity to implant the embryo. First solution that supports the science of uterine receptivity vs. a physician's estimates or inaccurate ultrasound. Market Launch early 2024.
4. Series B Open- Novel Evolution of Portable MRI and Robotics for Neurology treatments like Strokes and TBI.
5. Available for licensing: Phase I asset for Moderate-Severe Pain; Fast Track designation; Clinical Study on-going.
6. Available for licensing: Transdermal smart patch asset with Proprietary technology for Alzheimer’s Disease; IND filing in progress. Safer and non-irritable.
7. Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.
8. Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.